Replies to post #177170 on Biotech Values

[Double_Bagel]

If VRUS was worth $11 Billion, is it unreasonable for ENTA to be worth $5 Billion?

http://www.businesswire.com/news/home/20111121005623/en/Gilead-Sciences-Acquire-Pharmasset-11-Billion#.U1eVUfldXlc

I will be happy with even a $3 Billion buyout. VRUS when it was acquired, was not as far along as ENTA is now. I don't understand why ENTA is still so cheap. Isn't this derisked more than VRUS was when it was acquired?